안지오텐신 전환효소(ACE) 억제제 시장 : 약제별, 적응증별, 투여 경로별, 유통 채널별, 지역별

Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,000.3 Mn in 2025 and is expected to reach USD 13,179.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study

• This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.

Market Segmentation

• By Drugs
  • Benazepril
  • Perindopril
  • Trandfolapril
  • Captopril
  • Enalapril
  • Lisinopril
  • Others (Ramipril, etc.)
• By Indication
  • Hypertension
  • Coronary Artery Disease
  • Heart Failure
  • Chronic Kidney Disease
  • Scleroderma
  • Others (Migraine, etc.)
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan
  • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
  • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
  • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
  • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
  • Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Rising prevalence of hypertension
    • Growing Research and Development Activities
    • Increasing Awareness of Cardiovascular Health
  • Restraints
    • Patent Expirations
    • Side Effects and Safety Concerns
    • Side Effects and Safety Concerns
  • Opportunities
• Increasing Awareness of Cardiovascular Health
• Personalized medicine
• Combination therapies
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Benazepril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Perindopril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Trandfolapril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Captopril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Enalapril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Lisinopril
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Ramipril, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
• Coronary Artery Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
• Heart Failure
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
• Chronic Kidney Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
• Scleroderma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Others (Migraine, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • North Africa
    • Central Africa
    • Rest of Middle East & Africa

9. Competitive Landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Torrent Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mylan
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us